Diabetes
40 articles on Diabetes, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Medications and Supplement Needs: What You Should Know
As GLP-1 medications gain popularity for weight loss and diabetes management, understanding their impact on nutrient absorption is crucial. This article explores the link between these powerful drugs and the rising demand for supplements, offering insights from medical professionals and research.
6 min read
Generic Ozempic® Now Available in Canada: What You Need to Know
Apotex Inc. has launched Apo-Semaglutide Injection™, a generic version of Ozempic®, in Canada. This development brings a more affordable treatment option for type 2 diabetes management to Canadian patients and healthcare providers.
6 min read
GLP-1 Weight Loss Drugs: Usage Trends and What You Need to Know
The popularity of GLP-1 receptor agonists for weight management is soaring. This article delves into the latest trends, the science behind these medications, and essential considerations for patients and healthcare providers.
7 min read
GLP-1 Drugs and Hair Loss: What the Latest Research Reveals
New research suggests a connection between GLP-1 medications and temporary hair loss. Discover what this means for users of drugs like Ozempic, Wegovy, and Mounjaro, and how to navigate this common side effect.
8 min read
GLP-1 Drugs & Your Health: Beyond Weight Loss & 'Ozempic Breath'
GLP-1 agonists are revolutionizing weight management, but their effects extend far beyond the scale. This article delves into the science, the side effects like 'Ozempic breath,' and how these powerful medications are reshaping consumer habits and personal health journeys.
7 min read
Orforglipron: The New Oral GLP-1 Challenger in Weight Loss
A new daily pill, Orforglipron, is emerging as a significant contender in the weight loss and diabetes management space, offering a potential oral alternative to injectable GLP-1 medications. This article delves into its mechanisms, trial results, and what it means for the future of treatment.
7 min read
GLP-1 Medications and Hot Sauce: An Unexpected Link
The rise of GLP-1 medications has led to an unexpected surge in hot sauce sales. Explore the science behind altered taste perception and how it's influencing consumer choices.
6 min read
GLP-1 Medications & Weight Loss: What's Behind the Buzz?
The world of weight management has been significantly impacted by the emergence of GLP-1 receptor agonists. These medications, including popular drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have garnered immense attention for their effectiveness in promoting weight loss and improving metabolic health. But what exactly are these drugs, how do they work, and what should individuals considering them know?
7 min read
Coverage Unlocks Semaglutide's Potential for Obesity & Diabetes
Semaglutide, a powerful GLP-1 receptor agonist, transforms obesity and diabetes management but requires robust insurance coverage to deliver full benefits. Gasoyan and Rothberg emphasize access hurdles like prior authorizations that delay treatment. Addressing these ensures equitable health improvements amid rising metabolic disorders.
2 min read
Lupin, Galenicum Sign Semaglutide Deal for 23 Countries
Lupin has signed a licensing and supply agreement with Galenicum for injectable Semaglutide in 23 countries. Galenicum handles development and manufacturing, while Lupin manages approvals and commercialization. This boosts access to the GLP-1 drug for diabetes and obesity treatment.
2 min read
Understanding GLP-1 Drugs for Weight Loss & Diabetes
GLP-1 drugs mimic natural hormones to reduce hunger, slow digestion, and control blood sugar, aiding weight loss and type 2 diabetes. In Malaysia, over 54% of adults are overweight or obese, prompting Health Ministry rollout for vulnerable groups in 2026. Understand benefits, risks, and safe use guidelines.
3 min read
Using medications like Ozempic prior to pregnancy could heighten your chances of...
New studies indicate that halting popular GLP-1 medications before or shortly after conception results in more substantial weight increases during pregnancy and elevated chances of serious issues for both mother and child. This comes amid rising usage of these drugs for weight management and diabetes control. Experts emphasize the need for further investigation into balancing pre-pregnancy advantages with post-discontinuation risks.
4 min read
Ozempic and Weight Loss: An Examination with PhenQ Supplement Details
This article explores the use of Ozempic for weight loss, examining its effectiveness and safety. It also provides information on PhenQ as an alternative weight loss supplement.
8 min read
Unseen Effects: Potential Impacts of GLP-1 Weight Loss Medications
GLP-1 medications, while effective for weight loss, can have various side effects. Understanding these potential impacts is crucial for informed decision-making and patient care. These medications affect different parts of the body, leading to diverse reactions based on individual physiology.
7 min read
A GLP-1 Drug Changed My Life: My Friends' Reactions Surprised Me
ShantaQuilette Carter-Williams shares her experience with GLP-1 medications after facing serious health issues. Her story highlights the transformative impact on her health, lifestyle, and relationships.
7 min read
Are Replicas of Ozempic and Wegovy Safe? Understanding Compounded GLP-1s
Compounded semaglutide medications are custom-made by compounding pharmacies, containing the active ingredient in Ozempic and Wegovy. However, they are not FDA-approved and carry potential risks. This article explains what you need to know about these alternatives.
12 min read
Why Indians Should Use Ozempic Cautiously: Understanding the Reason
With the introduction of new weight-loss and diabetes drugs like Ozempic in India, endocrinologists are emphasizing the need for cautious and medically supervised use. Concerns arise particularly for individuals with a 'thin-fat' phenotype, who may experience adverse effects.
3 min read
Research Suggests Diabetes Drug Ozempic May Offer Brain Protection
Recent research suggests that GLP-1 medications like Ozempic, typically used for diabetes and weight management, might also positively impact brain health. The study indicates a lower risk of epilepsy development in individuals with Type 2 diabetes using these drugs.
3 min read
Shannonside Region: State Invests Nearly €2.63 Million on Ozempic | Shannonside.ie
New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.
1 min read
Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs
Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.
1 min read
Mounjaro by Eli Lilly Included in China's National Health Coverage for Diabetes
Mounjaro, a drug by Eli Lilly, is set to be added to China's state health insurance on January 1st. This inclusion could intensify competition among pharmaceutical companies. The move aims to improve access for China's large population.
1 min read
Feline Obesity Targeted by New 'Ozempic'-Like Drug Trial for Cats
A clinical trial is underway to test a new weight-loss treatment for cats using a drug class similar to Ozempic. The study, called MEOW-1, involves an implant administering medication to help overweight cats shed pounds.
3 min read
Dr. Reddy's Cleared by Delhi HC to Export Semaglutide Generics of Novo Nordisk
An Indian court has granted Dr. Reddy's Laboratories Ltd permission to manufacture and export generic versions of Novo Nordisk's diabetes and obesity medications. This decision comes before the global patent expirations in 2026. The ruling allows export to countries without patent protection.
2 min read
Ozempic, a Diabetes Medication, Slated for India Launch This Month
Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.
1 min read
Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
1 min read
Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
7 min read
Ozempic-like Medications: New Alert Issued Over Suicidal Thought Risk
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
4 min read
Berberine: Is This Supplement Truly 'Nature's Ozempic?' Experts Weigh In
Berberine, a compound found in several plants, has gained attention for its potential health benefits, including weight loss and blood sugar regulation. Some compare it to Ozempic, but experts caution about its effectiveness and safety compared to prescription medications.
4 min read
Ozempic 2.0? Exploring the Future of Weight Loss Medications
New weight loss drugs, potentially available in oral form, are under development by Eli Lilly and Novo Nordisk. These medications aim to manage type-2 diabetes and facilitate weight loss, potentially offering a more accessible and convenient alternative to current injectables.
4 min read
How Ozempic is Reshaping Thanksgiving Celebrations
The rise of GLP-1 medications is influencing how families celebrate Thanksgiving. With reduced appetites and changing dietary needs, many are finding innovative ways to balance tradition and health during the holidays.
3 min read
Novo Nordisk Reduces Wegovy Price Up to 37% in India Amid Mounjaro Competition
Novo Nordisk has reduced the price of Wegovy in India by as much as 37% to better compete with Eli Lilly's Mounjaro. This decision follows Mounjaro's rise to become the best-selling weight-loss medication in India by value.
2 min read
Ancient Chinese Medicine Berry Enhances Fat Metabolism in Mice with Diabetes
Research indicates that a berry utilized in traditional Chinese medicine can effectively restore healthy fat metabolism and enhance insulin sensitivity within a mouse model of diabetes. This finding suggests potential benefits for managing metabolic disorders.
4 min read
Cardioprotection Comparison: GLP-1 Drugs Show Similar Effects
Research comparing tirzepatide and semaglutide shows both medications reduce the risk of major cardiovascular events. The study highlights the early onset of cardioprotective effects, suggesting mechanisms beyond just weight loss. These findings support the integration of both agents into cardiovascular clinical practice.
2 min read
Real-World Data Highlights Heart Benefits of Diabetes Drugs Semaglutide and Tirzepatide
New research indicates that semaglutide and tirzepatide, drugs used for managing type 2 diabetes, exhibit heart-protective effects in real-world settings, mirroring findings from clinical trials. The study highlights the cardiovascular benefits these medications offer to patients in everyday clinical practice.
4 min read
Novo Nordisk Stock: Factors Contributing to This Week's Decline | The Motley Fool
Shares of Novo Nordisk have decreased substantially. This drop is influenced by increased competition in the GLP-1 market and a revised outlook for future growth. The global drugmaker faces headwinds from competitors like Eli Lilly.
2 min read
Reduced Gestational Diabetes Risk Observed with GLP-1 Use Before Pregnancy
A retrospective cohort study revealed that women taking GLP-1 receptor agonists before pregnancy exhibited a lower incidence of gestational diabetes. However, the study also indicated a potentially higher risk of pre-eclampsia in this group. These findings warrant further investigation due to the small sample size and potential confounding factors.
4 min read
Mounjaro Weight-Loss Injection Now Top-Selling Drug in India
According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.
3 min read
Novo Nordisk's Oral Wegovy Lowers Cardiovascular Risk Factors in Obesity Patients
The Phase III OASIS 4 trial revealed that Novo Nordisk's oral Wegovy (semaglutide) reduced cardiovascular risk factors in individuals with obesity. The study supports the drug's approval, showing improvements in C-reactive protein and serum triglycerides. Blood sugar control also improved among patients.
3 min read
Searching 'Weight' Can Yield Ozempic Results: A Drug Advertising Issue
A recent study highlights a potential issue in online drug advertising. Searching for terms like 'weight loss' can yield results for drugs like Ozempic, even if they are not FDA-approved for that specific purpose, raising concerns about misleading information.
3 min read
FDA Approves New Treatments: Oral Semaglutide & Lupus Nephritis Drug
The FDA has recently approved new treatments for two significant health challenges: cardiovascular risk reduction in type 2 diabetes and lupus nephritis. Learn about the potential benefits of these advancements and what they mean for patient care.
3 min read